Supplementary Data 1 from Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring <i>IDH1</i> or <i>IDH2</i> Mutations
James J. Harding, Do‐Youn Oh, Teresa Macarulla, Lipika Goyal, Andreas Varkaris, Lola‐Jade Palmieri, Masafumi Ikeda, Shunsuke Kondo, Li‐Yuan Bai, Makoto Ueno, Li‐Tzong Chen, Kyriakos P. Papadopoulos, Rachna T. Shroff, Sani H. Kizilbash, Antoine Hollebecque, Jorge Adeva, Rasha Cosman, Tomoya Yokota, Joon Oh Park, Anita Turk, Chih‐Yi Liao, Taroh Satoh, Mitesh J. Borad, Anthony B. El-Khoueiry, Nilofer S. Azad, Kurt A. Jaeckle, Herbert H. Loong, Wei Peng Yong, Mark H. Bender, Sunoj Chacko Varughese, Deepa Sachdeva, David B. Radtke, Ivelina Gueorguieva, Anna M. Szpurka, Hsiao-Rong Chen, Hui Liu, Xiangyuan Xu, Jordi Rodón